Actively Recruiting
Analgesic Efficacy of Maxigesic in Breast Cancer Surgery
Led by Yonsei University · Updated on 2025-07-20
84
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The present study aims to find a perioperative analgesic method that provides sufficient analgesia while reducing immune compromise in cancer surgery. This study is to investigate the analgesic effect and safety of Maxigesic inj. (a combination of acetaminophen 1000 mg and ibuprofen 300 mg), which is added to opioid-based IV-PCA in patients undergoing breast cancer surgery.
CONDITIONS
Official Title
Analgesic Efficacy of Maxigesic in Breast Cancer Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient aged 20 to 70 years with ASA classification 1 to 3 undergoing breast cancer surgery (cancer resection or reconstruction)
You will not qualify if you...
- ASA classification 4
- Allergy to acetaminophen, NSAIDs, or opioids
- Severe liver or renal dysfunction
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine
Seoul, South Korea
Actively Recruiting
Research Team
J
Jin Sun Cho
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here